Clinical perspectives and fundamental aspects of local cardiovascular and renal renin-angiotensin systems

Frontiers in Endocrinology

Volumn 5, Issue FEB, 2014, Pages

  De Mello, Walmor C ^a   Frohlich, Edward D ^b  

^a UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^b OCHSNER MEDICAL CENTER   (United States)

Author keywords

Arteries and kidney; Heart; Local renin angiotensin systems

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN III; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PRORENIN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

CARDIOVASCULAR DISEASE; CELL COMMUNICATION; CELL VOLUME; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; END STAGE RENAL DISEASE; ENDOTHELIAL DYSFUNCTION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY DISEASE; MITOCHONDRION; MULTICENTER STUDY (TOPIC); NONHUMAN; PROTEIN METABOLISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SALT INTAKE;

EID: 84901038638     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2014.00016     Document Type: Review

References (122)

1. Frohlich ED, Re RN, editors. Hypertensive heart diseases: time for new paradigms. In: The Local Cardiac Renin Angiotensin System. New York: Springer (2006). p. 1-5.
2. Frohlich ED, Re RN, editors. Are local renin angiotensin systems the focal points for understanding salt sensitivity in hypertension? In: The Local Cardiac Renin-Angiotensin-Aldosterone System. 2nd ed. New York: Springer (2009). p. 1-6.
3. De Mello WC, Frohlich ED, editors. Clinical import of the local renin angiotensin aldosterone systems. In: Renin Angiotensin System and Cardiovascular Disease. New York: Humana Press (2009). p. 7-14.
4. Bader M, Ganten D. Update on tissue renin-angiotensin systems. J Mol Med (Berl) (2008) 86(6):615-21. doi: 10.1007/s00109-008-0336-0.
5. Serneri GGN, Boddi M, Cecioni I, Vanni S, Coppo M, Papa ML, et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res (2001) 88:961-8. doi:10.1161/hh0901.089882.
6. Re RN. Local renin angiotensin systems in the cardiovascular system. In: De Mello WC, Frohlich ED, editors. Renin Angiotensin System and Cardiovascular Disease. New York: Humana Press (2009). p. 25-34.
7. Re RN, Cook JL. Intracrine function from angiotensin to stem cells. In: Frohlich ED, Re RN, editors. The Local Cardiac Renin Angiotensin System. New York: Humana Press (2009). p. 91-100.
8. Kurdi M, De Mello WC, Booz GW. Working outside the system: an update on unconventional behavior of the renin angiotensin system components. Int J Biochem Cell Biol (2005) 37:1357-67. doi:10.1016/j.biocel.2005.01.012.
9. Pfeffer MA, Pfeffer JM, Frohlich ED. Pumping ability of the hypertrophying left ventricle of the spontaneously hypertensive rat. Circ Res (1976) 38:423-9. doi:10.1161/01.RES.38.5.423.
10. Pfeffer MA, Pfeffer JM, Braunwald E. Influence of chronic captopril therapy on the infracted left ventricle of the rat. Circ Res (1985) 57:84-95. doi:10.1161/01.RES.57.1.84.
11. Pfeffer JM, Pfeffer MA, Mirsky I, Braunwald E. Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat. Proc Natl Acad Sci U S A (1982) 79:3310-4. doi:10.1073/pnas.79.10.3310.
12. Pfeffer MA, Braunwald E, Moye' LA, Basta L, Brown EJ Jr, Cuddy TE, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med (1992) 327:669-77. doi:10.1056/NEJM199209033271001.
13. Pfeffer MA, Frohlich ED. Improvements in clinical outcomes with the use of angiotensin-converting enzyme inhibitors: cross-fertilization between clinical and basic investigation. Am J Physiol Heart Circ Physiol (2006) 291:H2021-5. doi:10.1152/ajpheart.00647.2006.
14. Neri Serneri GG, Boddi M, Coppo M, Chechi T, Zarone N, Martelli M, et al. Evidence for the existence of a functional cardiac renin-angiotensin system in humans. Circulation (1996) 94:1886-95. doi:10.1161/01.CIR.94.8.1886.
15. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. Results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA (1967) 202:1028-34. doi:10.1001/jama.202.11.1028.
16. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA (1970) 213:1143-52. doi:10.1001/jama.213.7.1143.
17. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J. Factors of risk in the development of coronary heart disease-six year follow-up experience. The Framingham Study. Ann Intern Med (1961) 55:33-60. doi:10.7326/0003-4819-55-1-33.
18. Frohlich ED. Risk mechanisms in hypertensive heart disease. Hypertension (1999) 34:782-9. doi:10.1161/01.HYP.34.4.782.
19. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation (1991) 83:1771-9. doi:10.1161/01.CIR.83.5.1771.
20. Diez J, Querejata R, Lopez B, Gonzalez A, Larman M, Martinez-Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation (2002) 105:2512-7. doi:10.1161/01.CIR.0000017264.66561.3D.
21. Diez J. Towards a new paradigm about hypertensive heart disease. Hypertensive diseases: current challenges, new concepts and management. Med Clin North Am (2009) 93:637-45. doi:10.1016/j.mcna.2009.02.002.
22. Diez J, Frohlich ED. A translational approach to hypertensive heart disease. Hypertension (2010) 55:1-8. doi:10.1161/HYPERTENSIONAHA.109.141887.
23. Crowley SD, Gurley SB, Herrera MJ, Ruiz P, Griffiths R, Kumar AP, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A (2006) 103(47):17985-90. doi:10.1073/pnas.0605545103.
24. Frohlich ED. Salt and multiorgan damage in hypertension. Vascular stiffening and cardiorenal structural dysfunction responses. In: Safar ME, O'Rourke MF, Frohlich ED, editors. Pulse Pressure and Cardiovascular Stiffness. London: Springer-Verlag (2014) (in press).
25. Frohlich ED. The salt conundrum: a hypothesis. Hypertension (2007) 50:161-6. doi:10.1161/HYPERTENSIONAHA.107.088328.
26. Frohlich ED, Susic D. Sodium and its multiorgan targets. Circulation (2011) 124:1882-5. doi:10.1161/CIRCULATIONAHA.111.029371.
27. Appel LJ, Frohlich ED, Hall JE, Pearson TA, Sacco RL, Seals DR, et al. The importance of population-wide sodium reduction as a means to prevent cardiovascular disease and stroke: a call to action from the American Heart Association. Circulation (2011) 123:1138-43. doi:10.1161/CIR.0b013e31820d0793.
28. Whelton PK, Appel LJ, Sacco RJ, Anderson CAM, Antman EM, Campbell N, et al. Sodium, blood pressure, and cardiovascular disease: further evidence supporting the American Heart Association sodium reduction recommendations. Circulation (2012) 126:2880-9. doi:10.1161/CIR.0b013e318279acbf.
29. Kotchen TA, Cowley AW Jr, Frohlich ED. Salt in health and disease-a delicate balance. N Engl J Med (2013) 368:1229-37. doi:10.1056/NEJMra1212606.
30. Lewis EJ, Hunsicker LG, Bain RP, Rolude RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med (1993) 320:1456-62. doi:10.1056/NEJM199311113292004.
31. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med (2001) 345:861-9. doi:10.1056/NEJMoa011161.
32. Susic D, Frohlich ED, Kobori H, Shao W, Seth D, Navar LG. Salt-induced renal injury in SHRs is mediated by AT1 receptor activation. J Hypertens (2011) 29:17-26. doi:10.1097/HJH.0b013e3283440683.
33. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA (2003) 289:2560-72. doi:10.1001/jama.289.19.2560.
34. Ferder LF. Cellular oxidative stress, aging and the local RAS. In: Frohlich ED, Re RN, editors. The Local Cardiac Renin-Angiotensin-Aldosterone System. New York: Humana Press (2006). p. 201-17.
35. De Mello WC. Is an intracellular renin angiotensin system involved in the control of cell communication in heart? J Cardiovasc Pharmacol (1994) 23:640-6. doi:10.1097/00005344-199404000-00018.
36. De Mello WC, Danser AHJ. Angiotensin II and the heart-on the intracrine renin 431 angiotensin system. Hypertension (2000) 35:1183-8. doi:10.1161/01.HYP.35.6.1183.
37. De Mello WC. Intracellular angiotensin II regulates the inward calcium current in cardiac myocytes. Hypertension (1998) 32:076-82. doi:10.1161/01.HYP.32.6.976.
38. Re RN, Cook JL. The basis of an intracrine physiology. J Clin Pharmacol (2008) 48:344-50. doi:10.1177/0091270007312155.
39. Kumar R, Singh VP, Baker KM. The intracellular renin angiotensin system: implications in cardiovascular remodeling. Curr Opin Nephrol Hypertens (2008) 17:168-73. doi:10.1097/MNH.0b013e3282f521a8.
40. Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, Lammie AG, et al. Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem (2001) 276:36727-33. doi:10.1074/jbc. M103296200.
41. Bader M. Role of the local renin-angiotensin system in cardiac damage: a minireview focussing on transgenic animal models. J Mol Cell Cardiol (2002) 34:1455-62. doi:10.1006/jmcc.2002.2077.
42. Danser AH, van Kats JP, Admiraal PJ, Derkx FH, Lamers JM, Verdouw PD, et al. Cardiac renin and angiotensins. Uptake from plasma versus in situ synthesis. Hypertension (1994) 24(1):37-48. doi:10.1161/01.HYP.24.1.37.
43. Gwathmey TM, Alzayadneh EM, Pendergrass KD, Chappell MC. Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integr Comp Physiol (2012) 302(5):R518-30. doi:10.1152/ajpregu.00525.2011.
44. Tadevosyan A, Vaniotis G, Allen BG, Hébert TE, Nattel S. G protein-coupled receptor signalling in the cardiac nuclear membrane: evidence and possible roles in physiological and pathophysiological function. J Physiol (2012) 590(Pt 6):1313-30. doi:10.1113/jphysiol.2011.222794.
45. Cook JL, Mills SJ, Naquin R, Alam J, Re RN. Nuclear accumulation of the AT1 receptor in a rat vascular cell line: effects upon signal transduction and cellular proliferation. J Mol Cell Cardiol (2006) 40:696-707. doi:10.1016/j.yjmcc.2005.11.014.
46. Li XC, Zhuo JL. Intracellular ANG II directly induces in vitro transcription of TGF-beta1, MCP-1, and NHE-3 mRNAs in isolated rat renal cortical nuclei via activation of nuclear AT1a receptors. Am J Physiol Renal Physiol (2008) 294:C1034-45. doi:10.1152/ajpcell.00432.2007.
47. Robertson AL Jr, Khairallah PA. Angiotensin II: rapid localization in nuclei of smooth and cardiac muscle. Science (1971) 172:1138-9. doi:10.1126/science.172.3988.1138.
48. Zhuo JL, Li XC, Garvin JL, Navar LG, Carretero OA. Intracellular Ang II induces cytosolic Ca2+ mobilization by stimulating intracellular AT1 receptors in proximal tubule cells. Am J Physiol Renal Physiol (2006) 290:F1382-90. doi:10.1152/ajprenal.00269.2005.
49. Gonzalez-Villalobos RA, Janjoulia T, Fletcher NK, Giani JF, Nguyen MT, Riquier-Brison AD, et al. The absence of intrarenal ACE protects against hypertension. J Clin Invest (2013) 123:2011-23. doi:10.1172/JCI65460.
50. Bader M, Peters J, Baltatu O, Müller DN, Luft FC, Ganten D. Tissue renin-angiotensin systems: new insights from experimental animal models in hypertension research. J Mol Med (Berl) (2001) 79(2-3):76-102. doi:10.1007/s001090100210.
51. Reudelhuber TL, Bernstein KE, Delafontaine P. Is angiotensin II a direct mediator of left ventricular hypertrophy? Hypertension (2007) 49:1196-201. doi:10.1161/HYPERTENSIONAHA.106.075085.
52. Mazzolai L, Nussberger J, Aubert JF, Brunner DB, Gabbiani G, Brunner HR, et al. Blood pressure-independent cardiac hypertrophy induced by locally activated renin angiotensin system. Hypertension (1998) 31:1324-30. doi:10.1161/01.HYP.31.6.1324.
53. Domenighetti AA, Wang Q, Egger M, Richards SM, Pedrazzini T, Delbridge LM. Angiotensin II-mediated phenotypic cardiomyocyte remodeling leads to age-dependent cardiac dysfunction and failure. Hypertension (2005) 46:426-32. doi:10.1161/01.HYP.0000173069.53699.d9.
54. Xu J, Carretero OA, Liao TD, Peng H, Shesely EG, Xu J, et al. Local angiotensin II aggravates cardiac remodeling in hypertension. Am J Physiol Heart Circ Physiol (2010) 299(5):H1328-38. doi:10.1152/ajpheart.00538.2010.
55. Clausmeyer S, Sturebecher R, Peters J. An alternative transcript of the rat renin gene can result in a truncated prorenin that is transported into adrenal mitochondria. Circ Res (1999) 84:337-44. doi:10.1161/01.RES.84.3.337.
56. Peters J. Cytosolic (pro)renin and the matter of intracellular renin actions. Front Biosci (Schol Ed) (2013) 5:198-205. doi:10.2741/S366.
57. Peters J. Local renin-angiotensin systems in the adrenal gland. Peptides (2012) 34(2):427-32. doi:10.1016/j.peptides.2012.01.023.
58. De Mello WC. Influence of intracellular renin on heart cell communication. Hypertension (1995) 25:1172-7. doi:10.1161/01.HYP.25.6.1172.
59. De Mello WC. Intracellular renin alters the electrical properties of the intact heart ventricle of adult Sprague Dawley rats. Regul Pept (2013) 181:45-9. doi:10.1016/j.regpep.2012.12.015.
60. De Mello WC. Cardiac arrhythmias: the possible role of the renin angiotensin system. J Mol Med (2001) 79:103-8. doi:10.1007/s001090100195.
61. De Mello WC. Heart failure: how important is cellular sequestration? The role of the renin-angiotensin-aldosterone system. J Mol Cell Cardiol (2004) 37:431-8. doi:10.1016/j.yjmcc.2004.05.007.
62. Schefe JH, Menk M, Reinemund J, Effertz K, Hobbs RM, PandolfiPP, et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res (2006) 99:1355-66. doi:10.1161/01.RES.0000251700.00994.0d.
63. De Mello WC. On the pathophysiological implications of an intracellular renin receptor. Circ Res (2006) 99:1285-6. doi:10.1161/01.RES.0000253141.65450.fc.
64. Chappell MC. Nonclassical renin-angiotensin system and renal function. Compr Physiol (2012) 2:2733-52. doi:10.1002/cphy.c120002.
65. Santos RAS, Ferreira AJ, Braga TV, Bader M. Angiotensin converting enzyme 2, angiotensin (1-7) and Mas: new players of the renin angiotensin system. J Endocrinol (2013) 216:R1-17. doi:10.1530/JOE-12-0341.
66. Carey RM, Siragy HM. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev (2003) 24(3):261-71. doi:10.1210/er.2003-0001.
67. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, et al. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin regulate aminopeptidase. J Biol Chem (2001) 276(52):48623-6. doi:10.1074/jbc. C100512200.
68. Handa RK, Krebs LT, Harding JW, Handa SE. Angiotensin IV AT4-receptor system in the rat kidney. Am J Physiol (1998) 274(2 Pt 2):F290-9.
69. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci U S A (2003) 100(14):8258-63. doi:10.1073/pnas.1432869100.
70. Bader M. ACE2, angiotensin-(1-7), and Mas: the other side of the coin. Pflugers Arch (2013) 465(1):79-85. doi:10.1007/s00424-012-1120-0.
71. Nguyen G. The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology. Curr Opin Nephrol Hypertens (2007) 16(2):129-33. doi:10.1097/MNH.0b013e328040bfab.
72. Danser AH. (Pro)renin receptors: are they biologically relevant? Curr Opin Nephrol Hypertens (2009) 18(1):74-8. doi:10.1097/MNH.0b013e3283196aaf.
73. Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K. Isolation and identification of proangiotensin-12, apossible component of the renin angiotensin system. Biochem Biophys Res Commun (2006) 350:1026-31. doi:10.1016/j.bbrc.2006.09.146.
74. Nagata S, Kato J, Kuwasako K, Kitamura K. Plasma and tissue levels of proangiotensin-12 and components of the renin angiotensin system(RAS) following low or high salt-feeding in rats. Peptides (2010) 31:889-92. doi:10.1016/j.peptides.2010.02.008.
75. Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM. Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue. PLoS One (2011) 6:e28501. doi:10.1371/journal.pone.0028501.
76. Ferrario CM, Ahmad S, Nagata S, Simington SW, Varagic J, Kon N, et al. An evolving story of angiotensin-II-forming pathways in rodents and humans. Clin Sci (Lond) (2014) 126(7):461-9. doi:10.1042/CS20130400.
77. Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, et al. Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res (2013) 112:1104-11. doi:10.1161/CIRCRESAHA.113.301077.
78. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation (2008) 118:2523-32. doi:10.1161/CIRCULATIONAHA.108.784868.
79. Ichihara S, Senbonmatsu T, Price E Jr, Ichiki T, Gaffney FA, Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation (2001) 104:346-51. doi:10.1161/01.CIR.104.3.346.
80. Brede M, Hadamek K, Meinel L, Wiesmann F, Peters J, Engelhardt S, et al. Vascular hypertrophy and increased P70S6 kinase in mice lacking the angiotensin II AT2 receptor. Circulation (2001) 104:2602-7. doi:10.1161/hc4601.099401.
81. Steckelings UM, Paulis L, Namsolleck P, Unger T. AT2 receptor receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens (2012) 21:142-6. doi:10.1097/MNH.0b013e328350261b.
82. Wagenaar GT, Laghmani elH, Fidder M, Sengers RM, de Visser YP, de Vries L, et al. Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury. Am J Physiol Lung Cell Mol Physiol (2013) 305(5):L341-51. doi:10.1152/ajplung.00360.2012.
83. Ali Q, Wu Y, Hussain T. Chronic AT2 receptor activation increases renal ACE2 activity, attenuates AT1 receptor function and blood pressure in obese Zucker rats. Kidney Int (2013) 84(5):931-9. doi:10.1038/ki.2013.193.
84. Yiannikouris F, Gupte M, Putnam K, Thatcher S, Charnigo R, Rateri DL. Adipocyte deficiency of angiotensinogen prevents obesity-induced hypertension in male mice. Hypertension (2012) 60:1524-30. doi:10.1161/HYPERTENSIONAHA.112.192690.
85. González A, López R, Querejeta R, Díez J. Regulation of myocardial fibrillar collagen by angiotensin II. A role in hypertensive heart disease? J Mol Cell Cardiol (2002) 34:1585-93. doi:10.1006/jmcc.2002.2081.
86. Lauer D, Slavic S, Sommerfeld M, Thöne-Reineke C, Sharkovska Y, Hallberg A, et al. Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor β1 in the rat heart). Hypertension (2014) 63:e60-7. doi:10.1161/HYPERTENSIONAHA.113.02522.
87. Ludwig J, Kerscher S, Brandt U, Pfeiffer K, Getlawi F, Apps DK, et al. Identification and characterization of a novel 9.2-kDa membrane sector-associated protein of vacuolar proton-ATPase from chromaffin granules. J Biol Chem (1998) 273(18):10939-47. doi:10.1074/jbc.273.18.10939.
88. Binger K, Muller DN. Autophagy and the (pro)renin receptor. Front Cell Endocrinol (2013) 4:155. doi:10.3389/fendo.2013.00155.
89. Kinouchi K, Ichihara A, Sano M, Sun-Wada GH, Wada Y, Kurauchi-Mito A, et al. The (pro)renin receptor/ATP6AP2 is essential for vacuolar H+-ATAase asymmetry in murine cardiomyocytes. Circ Res (2010) 107:30-4. doi:10.1161/CIRCRESAHA.110.224667.
90. Massiéra F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc JM, et al. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASEB J (2001) 15(14):2727-9. doi:10.1096/fj.01-0457fje.
91. De Mello WC, Gerena Y. Eplerenone inhibits the intracrine and extracellular actions of angiotensin II on the inward calcium current in the failing heart. On the presence of an intracrine renin angiotensin aldosterone system. Regul Pept (2008) 151(1-3):54-60. doi:10.1016/j.regpep.2008.06.003.
92. De Mello WC, Re RN. Systemic versus local renin angiotensin systems. An overview. In: De Mello WC, Frohlich ED, editors. Renin Angiotensin System and Cardiovascular Disease. New York: Humana Press (2009). p. 1-5.
93. Re RN. The implication of intracrine hormone action for physiology and medicine. Am J Physiol Heart Circ Physiol (2003) 284:H751-7. doi:10.1152/ajpheart.00935.2002.
94. De Mello WC. Intracellular angiotensin II increases the total potassium current and the resting potential of arterial myocytes from vascular resistance vessels of the rat. Physiological and pathological implications. J Am Soc Hypertens (2013) 7(3):192-7. doi:10.1016/j.jash.2013.02.003.
95. Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol (1995) 268(4 Pt 1):C799-822.
96. Abadir PM, Walston JD, Carey RM. Subcellular characteristics of functional intracellular renin-angiotensin systems. Peptides (2012) 38(2):437-45. doi:10.1016/j.peptides.2012.09.016.
97. Lange F, Busch G, Ritter M, Volkl H, Waldegger S, Gulbins E, et al. Functional significance of cell volume regulatory mechanisms. Physiol Rev (1998) 78:247-306.
98. De Mello WC. Novel aspects of angiotensin II action in the heart. Implications to myocardial ischemia and heart failure. Regul Pept (2011) 166(1-3):9-14. doi:10.1016/j.regpep.2010.10.003.
99. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin (1-7). Hypertension (1997) 30:535-41. doi:10.1161/01.HYP.30.3.535.
100. De Mello WC, Ferrario CM, Jessup JA. Beneficial versus harmful effects of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart. J Renin Angiotensin Aldosterone Syst (2007) 8:74-80. doi:10.3317/jraas.2007.015.
101. De Mello WC. Angiotensin (1-7) re-establishes impulse conduction in cardiac muscle during ischaemia-reperfusion. The role of the sodium pump. J Renin Angiotensin Aldosterone Syst (2004) 5(4):203-8. doi:10.3317/jraas.2004.041.
102. De Mello W, Rivera M, Rabell A, Gerena Y. Aliskiren, at low doses, reduces the electrical remodeling in the heart of the TGR(mRen2)27 rat independently of blood pressure. J Renin Angiotensin Aldosterone Syst (2013) 14(1):23-33. doi:10.1177/1470320312463832.
103. Zou Y, Akazawa H, Qin Y, Sano M, Takano H, Minamino T, et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol (2004) 6:499-506. doi:10.1038/ncb1137.
104. De Mello WC. Mechanical stretch reduces the effect of angiotensin II on potassium current in cardiac ventricular cells of adult Sprague Dawley rats. On the role of AT1 receptors as mechanosensors. J Am Soc Hypertens (2012) 6(6):369-74. doi:10.1016/j.jash.2012.08.006.
105. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin converting enzyme related carboxypeptidase (ACE2) converts angiotensin I to angiotensin (1-9). Circ Res (2000) 87:E1-9. doi:10.1161/01.RES.87.5.e1.
106. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem (2000) 275:33238-43. doi:10.1074/jbc. M002615200.
107. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature (2002) 417(6891):822-8. doi:10.1038/nature00786.
108. Ferrario CM, Trask AJ, Jessup JA. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol (2005) 289:H2281-90. doi:10.1152/ajpheart.00618.2005.
109. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, et al. Increased angiotensin (1-7) forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin converting enzyme homolog, ACE2. Circulation (2003) 108:1707-12. doi:10.1161/01.CIR.0000094734.67990.99.
110. De Mello WC. Cell swelling, impulse conduction, and cardiac arrhythmias in the failing heart. Opposite effects of angiotensin II and angiotensin (1-7) on cell volume regulation. Mol Cell Biochem (2009) 330(1-2):211-7. doi:10.1007/s11010-009-0135-0.
111. Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu PP, et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail (2009) 2:446-55. doi:10.1161/CIRCHEARTFAILURE.108.840124.
112. Camargo de Andrade MC, Di Marco GS, de Paulo CI, Mortara RA, Sabatini RA, Pesquero JB, et al. Expression and localization of N-domain ANG I-converting enzymes in mesangial cells in culture from spontaneously hypertensive rats. Am J Physiol Renal Physiol (2006) 290:F364-F375. doi:10.1152/ajprenal.00110.2005.
113. Campbell DJ, Zeitz CJ, Esler MD, Horowitz JD. Evidence against a major role for angiotensin converting enzyme-related carboxypeptidase (ACE2) in angiotensin peptide metabolism in the human coronary circulation. J Hypertens (2004) 22:1971-6. doi:10.1097/00004872-200410000-00020.
114. Zimmerman D, Burns KD. Angiotensin-(1-7) in kidney disease: a review of the controversies. Clin Sci (2012) 123:333-46. doi:10.1042/CS20120111.
115. Zannad F, Alla F, Dousset B, Perez A, Pitt B; on behalf of RALES Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Circulation (2000) 102(22):2700-6. doi:10.1161/01.CIR.102.22.2700.
116. Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K, et al. Aldosterone production is activated in the failing ventricle in humans. Circulation (2001) 103:72-7. doi:10.1161/01.CIR.103.1.72.
117. Messaoudi S, Azibani F, Delcayre C, Jaisser F. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol (2012) 350(2):266-72. doi:10.1016/j.mce.2011.06.038.
118. Bender SB, McGraw AP, Jaffe IZ, Sowers JR. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes (2013) 62(2):313-9. doi:10.2337/db12-0905.
119. Aroor AR, Demarco VG, Jia G, Sun Z, Nistala R, Meininger GA, et al. The role of tissue renin-angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front Endocrinol (Lausanne) (2013) 4:161. doi:10.3389/fendo.2013.00161.
120. Hitomi H, Kiyomoto H, Nishiyama A, Hara T, Moriwaki K, Kaifu K, et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension (2007) 50:750-5. doi:10.1161/HYPERTENSIONAHA.107.093955.
121. Briet M, Schiffrin EL. The role of aldosterone in the metabolic syndrome. Curr Hypertens Rep (2011) 13:163-72. doi:10.1007/s11906-011-0182-2.
122. De Mello WC. Spironolactone enhances the beneficial effect of aliskiren on cardiac structural and electrical remodeling in TGR(mRen2)27 rats. J Renin Angiotensin Aldosterone (2013). doi:10.1177/1470320313497818.